The UK and US have finalized a key bilateral deal that will maintain no tariffs on British medicine products going into the American market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has agreed to raise expenditure on drugs through the public health system. This move ensures that duties on these crucial products will be held at zero for a period of the next three years.
This development follows recent statements to hike import taxes on patented pharmaceutical products, with figures mentioned as high as 100%.
"This deal between the UK reinforces the worldwide climate for innovative medicines and establishes long-overdue balance to transatlantic drug exports," an announcement noted.
Trade Significance
Drugs are one of the the United Kingdom's largest exports to the United States, which is clearly the biggest buyer for large British pharmaceutical firms.
Trade data show that in the year prior to last September, the UK sold drugs totaling over eleven billion pounds to the US. This figure represented nearly one-fifth of total UK exports in that timeframe.
"This deal secures work, stimulates funding and sets the stage for the UK to establish itself as a international leader for biotech and pharma," a minister remarked.
Detailed British Pledges
The agreement involves several specific changes from the British government:
- Higher Cost Ceiling: The UK will lift the price threshold at which it deems new therapies to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a aim to increase overall public funding on medicines from 0.3 percent of GDP to 0.6% over the next decade.
- Payback Limit: The percentage manufacturers must return to the NHS to control costs will be restricted at 15%. Last year, repayments topped 20%.
Industry Background
This agreement comes amid a long-running dispute between the sector and the UK government over spending levels and NHS adoption.
This friction were intensified by arguments that US consumers were paying significantly more for the identical medicines than patients in the UK and Europe.
Recently, several large pharmaceutical investments in the UK have been halted or cancelled, while substantial funding commitments have been pledged toward American operations.
A senior figure stated that the NHS had to spend more on drugs, noting that its expenditure on drugs had shrunk as a share of its overall budget over the last ten years.